FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...
– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also ...
Learn the inner workings of The Necrobinder, the brand new necromancer who can create a boss-sized ally in Slay the Spire 2.
Upstream Bio said a Phase 2 clinical trial for its respiratory-disease treatment met its primary endpoint in two dosing regimens, but that a third treatment group didn't see consistent improvements.
Lucas is a writer and narrative designer from Argentina with over 15 years of experience writing for games and news. He keeps a watchful eye at the gaming world and loves to write about the hottest ...
Lucas is a writer and narrative designer from Argentina with over 15 years of experience writing for games and news. He keeps a watchful eye at the gaming world and loves to write about the hottest ...
15d
Croft Edwards, MCC, Releases The Liquid Accordion, a New Guide to Somatic Leadership and Coaching
The book offers a clear primer on applying somatic and embodiment principles in leadership and one-on-one coaching.
Here are all the clues, exactly as depicted in The Division 2 Mutiny. SHD Agents must decipher the clues and complete the respective missions: "Take out the True Sons before they derail the uprising." ...
Third Person Shooters Marathon looks miles ahead of Arc Raiders in one key area: "Anyone found to be cheating will be permabanned" Third Person Shooters Arc Raiders devs love the self-described ...
£30m midfielder raves about how Rosenior improved him “technically” – Chelsea should have signed him
The Guardian have done a really good interview with Habib Diarra, the former, Strasbourg captain now impressing with Sunderland after a £30m move in the summer. He only had one season together with ...
(RTTNews) - Upstream Bio (UPB) will host a webcast today to present top-line results from its Phase 2 VALIANT trial evaluating Verekitug, a first-in-class antagonist of the thymic stromal ...
BACKGROUND: Forecasts for the future prevalence of cardiovascular disease and stroke are crucial to guide efforts to improve health outcomes across the life course for women. METHODS: Using historical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results